Edgewise Swings to $1.17B Profit on Sevasemten Sale, $1.74B Cash, Phase 3 HCM Trial by Year-End
EWTX has more than doubled off its 52-week low of $16.7.
Summary
Edgewise posted Q3 2026 net income of $1,166.2 million, or $10.71 per basic share, versus a $40.7 million loss a year ago, almost entirely from the $1.348 billion gain on the July sale of its sevasemten muscular dystrophy business to Servier. The company collected $1.396 billion in upfront cash at closing, lifting cash, cash equivalents and marketable securities to roughly $1,743.9 million as of September 30 — a balance that dwarfs the operating burn of $46.1 million for the quarter. R&D fell to $31.6 million from $37.5 million on lower sevasemten costs, while G&A rose to $14.6 million from $9.4 million as headcount expanded. On the pipeline, management said the Phase 3 trial of EDG-7500 in obstructive and nonobstructive HCM remains on track to start by year-end 2026, and the first patient has been dosed in the Phase 2 EQUINOX-HFpEF study of EDG-15400. The profit is a one-time transaction gain, not operating earnings — the real story is the cash pile funding two cardiovascular programs and the imminent Phase 3 start.
At the time of this announcement, EWTX was trading at $37.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1B. The 52-week trading range was $16.70 to $48.51. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.